Abstract: A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death.

Abstract: A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death.

Abstract: Methods, processes and systems for procuring, isolating and cryopreserving at least one viable, multipotent maternal placental stem cell is provided. Viable maternal placental stem cells are also provided. The maternal placental stem cell of the invention expresses the cell surface marker CD117 and at least one of the cell surface markers selected from the group consisting of CD29, CD44, CD73, CD90, CD105, CD166, SSEA-3 and SSEA-4 and has low or no expression of at least one of the cell surface markers selected from the group consisting of CD34, CD45, CD133, TRA-1-60 and TRA-1-81. The methods and process comprise generally obtaining a piece of placental tissue from a whole placenta, disaggregating the placental tissue with mechanical separation or enzymatic digestion, collecting and concentrating placental cells comprising maternal placental cells with centrifugation and optionally cryopreserving the placental cells. Additional steps for selecting and culturing the maternal placental stem cells is provided.

Abstract: Methods, processes and systems for procuring, isolating and cryopreserving fetal placental cells are provided. A population of fetal placental cells is also provided.